Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.

CONCLUSION: rFVIIa use in the context of emicizumab prophylaxis does not change the rFVIIa safety profile as described in the product information. This article is protected by copyright. All rights reserved.
PMID: 31124272 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - May 23, 2019 Category: Hematology Authors: Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S Tags: J Thromb Haemost Source Type: research